{"entity":{"id":"nct07001618","kind":"trial","name":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot","aka":["IMMUNOLIFE2"],"tldr":"A phase 2 trial of cemiplimab, cisplatin, pemetrexed, bevacizumab and other drugs in lung cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","summary":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT07001618 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 162 participants, started 2025-11-17 and due to reach its primary completion in 2030-09. Interventions recorded: MaaT033 capsule; Cemiplimab; Cisplatin; Carboplatine; Pemetrexed (Alimta); Bevacizumab; Paclitaxel; gemcitabine; Docetaxel; Vinorelbine i.v. 25 mg/m²; Vinorelbine oral. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: Disease Control Rate (DCR). Lung eligibility wording from the registry: \"Histologically confirmed diagnosis of NSCLC (adenocarcinoma versus squamous cell carcinoma versus others)\". Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07001618","url":"https://clinicaltrials.gov/study/NCT07001618"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","cytotoxic-chemotherapy","monoclonal-antibody","platinum"],"targets":[],"drugs":["cemiplimab","cisplatin","pemetrexed","bevacizumab","paclitaxel","gemcitabine","docetaxel"],"companies":["maat-pharma","regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07001618","phase":"2","setting":"A Randomized Multicenter Phase II Trial Evaluating Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab (CB) Versus Best Investigator's Choice (BIC) in Resistance to PD-1/PD-L1 Blockade Due to Antibiotics (ATB) Uptake in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","enrolled":162,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07001618/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"maat-pharma","kind":"company","name":"MaaT Pharma","route":"/companies/maat-pharma/"},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}